-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16

Benzinga·06/17/2026 12:35:38
Listen to the news
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $14 to $16.